

TeneoTwo Enters into Agreement to be Acquired by AstraZeneca

Client News July 5, 2022

Gunderson Dettmer is representing client TeneoTwo, a developer of therapeutic antibodies, in its pending acquisition by AstraZeneca, a bio-pharmaceutical company that focuses on the discovery, development and commercialization of prescription medicine. AstraZeneca will acquire TeneoTwo's TNB-486, a Phase I clinical-stage CD19/CD3 T-cell engager, which will help accelerate the development of a new medicine for B-cell malignancies.

In the announcement of the acquisition, Senior Vice President of AstraZeneca Anas Younes said, "By redirecting the body's natural immune response to target B-cell malignancies, TNB-486 alone or in combination with CD20-targeted therapy could potentially deepen clinical responses and improve patient outcomes. We believe this innovative molecule, which was designed to optimize the therapeutic window of T-cell activation, will enable us to explore novel combinations that have the potential to become new standards of care in this setting."

The Gunderson Dettmer deal team was co-led by partner Michael Irvine and associates Nate Gray and Julie Mahoney, and included of counsel Craig Olshan and associates Brenden Glapion, Scout Moran, Alex Lee and Shawn Trabanino.

Companies:

AstraZeneca

Related People

PARTNER

P +1 415 801 4880

Nathaniel F. Gray ASSOCIATE

P +1 415 801 4922

Julie C. Mahoney ASSOCIATE P +1 650 463 5220

Craig W. Olshan
PARTNER
P +1 650 463 5413

Brenden Glapion
ASSOCIATE
P +1 650 463 5251

Alex Lee ASSOCIATE P +1 858 436 8057

Related Services

Late-Stage Company
Mergers & Acquisitions

Featured Insights

FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific Islander Heritage (AAPI) Month

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California Al Transparency Act

INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad

INSIGHTS

Tech Brew Interviews Aaron Rubin in "Where the legal battle stands around copyright and AI training"

CLIENT NEWS

Latin America Fintech Belvo Announces \$15M Funding